I
ncreased adiposity and direct effects of glucocorticoid excess on muscle, liver, and b-cells are responsible for the high prevalence of impaired glucose tolerance (IGT) and type 2 diabetes in patients with Cushing syndrome (CS) (1, 2) . In the SEISMIC study, the glucocorticoid receptor antagonist mifepristone improved glucose tolerance and produced weight loss over 24 weeks in CS patients (3) . Using oral glucose tolerance test data from SEISMIC, our goal was to assess whole-body insulin sensitivity (Matsuda index), b-cell function (insulinogenic index, homeostasis model assessment-b [HOMAb]), disposition index (4, 5) , weight (WT), and waist circumference (WC) over time. Complete data in patients not receiving insulin were available in 19 patients, 8 with diabetes and/or IGT (C-DM) and 11 with hypertension only (C-HT).
Within-group comparisons for change over time were analyzed with a mixedeffects repeated measures two-way ANOVA with cohort (C-DM and C-HT), time, and cohort by time interaction as fixed effects; unpaired Student t tests were used to assess differences between groups (Table 1) . Matsuda index improved in the total population, with the greatest improvement occurring between baseline and week 6 and lesser changes occurring from week 6 to 24. Further analysis (piecewise linear mixed-model regression) showed that a two-phase model (0-6 weeks and 6-24 weeks) for Matsuda index change over time was better than the linear model (P = 0.007; Akaike information criteria). In contrast, WT and WC declined linearly over the 24 weeks, with the largest declines occurring during the final 18 weeks of treatment (baseline to week 6: WT, 21.19 6 3.17%, P = 0.1; WC, 21.31 6 3.38%, P = 0.07; week 6 to 24: WT, 26.66 6 6.52%, P = 0.0003; WC, 26.36 6 5.83%, P = 0.0002, ANOVA). At baseline, C-DM patients had compromised insulin secretory responses, as evidenced by lower insulinogenic index 0-30 , insulinogenic index 0-120 , and HOMA-b. C-HT patients experienced declines in insulinogenic index 0-30, insulinogenic index 0-120 , and HOMA-b by week 24, whereas these parameters trended nonsignificantly up in C-DM patients. The disposition index was lower at baseline in C-DM patients than C-HT patients. Individual C-DM patients tended more often to have increases in disposition index than C-HT patients (3.079 6 4.387 vs. 21.739 6 5.444, P = 0.063, respectively). Adiponectin levels increased from baseline to week 24 in C-HT subjects only in a temporal pattern that closely followed changes in WT and WC.
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